The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.
 
Thai Huu Ho
No Relationships to Disclose
 
Robert Charles Gagnon
Employment - Novartis
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis
 
Yuan Liu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
F. Stephen Hodi
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca; Merck; Verastem
Patents, Royalties, Other Intellectual Property - BioGenex
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)